

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mega Genomics Limited
美因基因有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6667)

**INTERIM RESULTS ANNOUNCEMENT FOR
THE SIX MONTHS ENDED 30 JUNE 2025**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Mega Genomics Limited (the “**Company**”) is pleased to announce the unaudited interim condensed consolidated results of the Company and its subsidiaries (collectively, the “**Group**”) for the six months ended 30 June 2025 (the “**Reporting Period**”).

In this announcement, “we”, “us” and “our” refer to the Company and, where the context otherwise requires, the Group. Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments. Any discrepancies in any table between totals and sums of amounts listed therein are due to rounding.

BUSINESS REVIEW AND OUTLOOK

Business Review

Overview

As a leading genetic testing platform company in China, we focus on consumer genetic testing services and ancillary services and cancer screening services and ancillary services. As of 30 June 2025, we had performed over 24 million genetic tests in total.

* *For identification purpose only*

According to Frost & Sullivan, we were the largest consumer genetic testing platform in China in terms of the cumulative number of tests administered as of 31 December 2021. We were the largest genetic testing platform for cancer screening in China as measured by the number of tests administered in 2020. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the prospectus of the Company dated 10 June 2022 (the “**Prospectus**”).

Business

During the Reporting Period, the Company achieved operating revenue of RMB81.3 million, representing a year-on-year decrease of 24.2%; and net profit of RMB27.3 million, representing a year-on-year decrease of 26.3%. The year-on-year decrease in operating revenue and net profit for the Period was mainly due to the Company’s adjustment of its sales strategy, which led to a temporary decrease in operating revenue; while costs such as labor costs, rent and depreciation being relatively fixed, resulting in a reduction in net profit.

As of 30 June 2025, we covered healthcare institutions in more than 340 cities in China. Our sales and marketing network allows us to deliver genetic testing services to a large portion of the Chinese population. In addition, we cooperate with various e-commerce and online healthcare platforms to expand and enhance our sales and marketing network.

Financial Highlights

| | For the six months ended 30 June | | |
|--|---|----------------|------------------------|
| | 2025 | 2024 | Year-on-year change |
| | <i>RMB’000</i> | <i>RMB’000</i> | |
| | (Unaudited) | (Unaudited) | |
| Revenue | 81,281 | 107,291 | (24.2%) |
| Consumer genetic testing services and ancillary services | 75,947 | 104,419 | (27.3%) |
| Cancer screening services and ancillary services | 5,334 | 2,872 | 85.7% |
| Gross profit | 60,140 | 69,618 | (13.6%) |
| Gross profit margin | 74.0% | 64.9% | 9.1 percentage points |
| Net profit | 27,261 | 36,969 | (26.3%) |
| Net profit margin | 33.5% | 34.5% | (1.0 percentage point) |

Revenue

For the six months ended 30 June 2025, we achieved operating revenue of RMB81.3 million, representing a decrease of RMB26.0 million or 24.2% as compared to RMB107.3 million for the same period in 2024. Of which, the revenue generated from consumer genetic testing services and ancillary services and cancer screening services and ancillary services for the six months ended 30 June 2025 amounted to RMB75.9 million and RMB5.3 million, respectively. The year-on-year decrease in operating revenue was mainly due to the Company's adjustment of its sales strategy, which led to a temporary decrease in operating revenue.

Gross Profit and Gross Profit Margin

For the six months ended 30 June 2025, our consolidated gross profit amounted to RMB60.1 million, representing a year-on-year decrease of 13.6%, of which RMB56.8 million and RMB3.3 million of gross profit were attributable to consumer genetic testing services and ancillary services and cancer screening services and ancillary services, respectively. The year-on-year decrease in consolidated gross profit was driven by a short-term decrease in revenue resulting from the Company's adjustment of its sales strategy, while costs such as labor costs, rent and depreciation being relatively fixed.

For the six months ended 30 June 2025, our consolidated gross profit margin was 74.0%, representing a year-on-year increase of 9.1 percentage points. For the six months ended 30 June 2025, the gross profit margin for our consumer genetic testing services and ancillary services was 74.8%, representing a year-on-year increase of 9.7 percentage points, driven by the optimization of our product and service portfolio and our ability to effectively control costs. The gross profit margin for our cancer screening services and ancillary services was 62.1%, representing a year-on-year increase of 4.6 percentage points, driven by our enrichment of product categories for our cancer screening services and ancillary services, while costs such as labor costs and rent being relatively fixed.

Prospects and Outlook

Further exploiting the consumer genetic testing market in China

According to Frost & Sullivan, the penetration of the consumer genetic testing market in China is expected to grow from 0.8% to 11.6% from 2020 to 2030. During this process, more industry standards regarding the consumer genetic testing industry will be gradually established and the prevention and treatment guidelines or expert consensus for common diseases will be formed gradually. We believe that it is critical to expedite the establishment of industry standards.

We will strengthen our partnerships with industry leaders to establish industry standards through cooperation with key opinion leaders. This includes organizing academic meetings, collaborating with experts in scientific research, and conducting retrospective data analysis, etc. We will also strengthen our efforts to accelerate the education of medical institutions and increase market penetration more quickly by popularizing industry standards.

Meanwhile, in order to continuously consolidate our leading position in the consumer genetic testing market, we constantly upgrade and launch new products to meet the huge domestic consumer genetic market demand.

Further exploiting the cancer screening test market in China

The current market is basically aware of cancer screening. In particular, in the field of digestive tract tumors, blood methylation screening for intestinal cancer has gradually and widely reached consumers and has achieved good response. We will further strengthen the automation level of production to reduce the production cost and accelerate the R&D and application of blood methylation products for digestive tract tumors to improve the sensitivity and specificity of screening, so as to make the blood methylation screening for intestinal cancer have better socio-economic value.

We will continue diversifying our cancer screening product categories and product lines, such as innovative screening products for esophageal cancer, endometrial cancer, and bladder cancer, building a one-stop early cancer screening product matrix covering multiple cancer types and technological pathways. In the future, the Company will closely follow clinical needs and technological development trends, continuously increase R&D investment, promote the implementation of more cost-effective early cancer screening products, help achieve the public health goal of early detection, early diagnosis, and early treatment of cancer, and contribute to improving the health of the nation.

Expanding our R&D strength and enriching our product matrix

We will vigorously expand our R&D strength. In line with our R&D efforts, we plan to recruit more professionals to strengthen our internal R&D team and supplement our internal R&D strength by collaborating with renowned domestic and international academic and medical institutions.

Our self-developed ApoE gene testing kits detect ApoE gene mutations and assess the risk of Alzheimer's disease, which can generate synergistic effects with our Alzheimer's disease screening products, and are also used for medication guidance for patients with hyperlipidemia. The product has officially obtained the medical device registration certificate issued by the National Medical Products Administration in 2025.

Our self-developed folate metabolic capacity assessment testing kits detect the MTHFR gene polymorphisms and assess the metabolic capacity of folate in order to guide pregnant women to supplement folate and prevent neonatal defects, including neural tube defects, and are also used for medication guidance for patients with hyperhomocysteinemia. The product has officially obtained the medical device registration certificate issued by the National Medical Products Administration in 2025.

Our self-developed fecal occult blood intestinal cancer screening and transferrin screening products have been granted the Registration Certificate for Medical Device and have achieved mass production.

We will continue to develop more screening products that have both social significance and economic value and meet our customers' demand for convenient testing.

Making selective geographic expansion and acquisition opportunities

We plan to build a manufacturing laboratory to enhance geographic coverage, improve reporting cycles and reduce operating costs. We will optimize the production process, adopt a new production system for the new laboratory, and substantially shorten the product reporting time, to further improve customer experience.

We also plan to make prudent investments to complement our internal growth. We plan to acquire product candidates with significant market potential or technological frontiers as and when appropriate, so as to complement our existing product portfolio and create synergies with our R&D, manufacturing and channel systems.

MANAGEMENT DISCUSSION AND ANALYSIS

The following table sets forth our unaudited condensed consolidated statement of profit or loss for the periods indicated, together with the changes from the six months ended 30 June 2024 to the same period in 2025, presented as a percentage:

| | For the six months ended 30 June | | |
|---|---------------------------------------|---------------------------------------|--------------------------|
| | 2025 <i>RMB'000</i> (Unaudited) | 2024 <i>RMB'000</i> (Unaudited) | Year-on-year change % |
| Revenue | 81,281 | 107,291 | (24.2%) |
| Cost of sales | <u>(21,141)</u> | <u>(37,673)</u> | <u>(43.9%)</u> |
| Gross profit | 60,140 | 69,618 | (13.6%) |
| Other income and gains | 4,210 | 3,438 | 22.5% |
| Selling and distribution expenses | (10,426) | (13,609) | (23.4%) |
| Administrative expenses | (17,987) | (17,511) | 2.7% |
| Impairment (losses)/reversal of impairment on trade receivables, net | (1,263) | 2,686 | N/A |
| Other expenses | (1,004) | (643) | 56.1% |
| Finance costs | <u>(528)</u> | <u>(937)</u> | <u>(43.6%)</u> |
| Profit before tax | 33,142 | 43,042 | (23.0%) |
| Income tax expenses | <u>(5,881)</u> | <u>(6,073)</u> | <u>(3.2%)</u> |
| Profit for the period | <u>27,261</u> | <u>36,969</u> | <u>(26.3%)</u> |

Revenue

We organize our principal business into two segments, namely consumer genetic testing services and ancillary services and cancer screening services and ancillary services.

The table below sets forth our revenue by operating segment for the periods indicated (presented in figures and as a percentage of total revenue).

| | For the six months ended 30 June | | | |
|--|----------------------------------|--------------|----------------|--------|
| | 2025 | | 2024 | |
| | <i>RMB'000</i> | % | <i>RMB'000</i> | % |
| | (Unaudited) | | (Unaudited) | |
| Consumer genetic testing services and ancillary services | 75,947 | 93.4% | 104,419 | 97.3% |
| Cancer screening services and ancillary services | 5,334 | 6.6% | 2,872 | 2.7% |
| Total | 81,281 | 100% | 107,291 | 100.0% |

- Consumer genetic testing services and ancillary services. For the six months ended 30 June 2025, our revenue from consumer genetic testing services and ancillary services amounted to RMB75.9 million, representing a year-on-year decrease of 27.3%, which was because of the Company's adjustment of its sales strategy, which led to a temporary decrease in our revenue from consumer genetic testing services and ancillary services during the Reporting Period.
- Cancer screening services and ancillary services. For the six months ended 30 June 2025, our revenue from cancer screening services and ancillary services amounted to RMB5.3 million, representing a year-on-year increase of 85.7%, which was because the Company enriched product categories of cancer screening services and ancillary services, resulting in an increase in revenue from cancer screening services and ancillary services during the Reporting Period.

Cost of Sales

Our cost of sales consists primarily of labor costs and business operation and other costs. Business operation and other costs mainly include the costs of raw materials, testing services, printing, express delivery, clusters, rent, property utilities, etc. The table below sets forth a breakdown of cost of sales by nature for the periods indicated (presented in figures and as a percentage of cost of sales).

| | For the six months ended 30 June | | | |
|---------------------------------------|----------------------------------|----------------------|----------------------|----------------------|
| | 2025 | | 2024 | |
| | <i>RMB'000</i> | <i>%</i> | <i>RMB'000</i> | <i>%</i> |
| | (Unaudited) | | (Unaudited) | |
| Labor costs | 5,024 | 23.8% | 5,060 | 13.4% |
| Business operation and other costs | <u>16,117</u> | <u>76.2%</u> | <u>32,613</u> | <u>86.6%</u> |
| Total | <u><u>21,141</u></u> | <u><u>100.0%</u></u> | <u><u>37,673</u></u> | <u><u>100.0%</u></u> |

Our cost of sales decreased by 43.9% from RMB37.7 million for the six months ended 30 June 2024 to RMB21.1 million for the same period in 2025. Such decrease was primarily attributable to the decrease in revenue.

Gross Profit and Gross Profit Margin

For the six months ended 30 June 2024 and 2025, our gross profit amounted to RMB69.6 million and RMB60.1 million, respectively. The gross profit margin was 64.9% and 74.0%, respectively. The table below sets forth a breakdown of gross profit and gross profit margin by operating segment for the periods indicated (presented in figures and as a percentage of total gross profit).

| | For the six months ended 30 June | | | |
|--|---|-------------------------------|-------------------------------|-------------------------------|
| | 2025 | | 2024 | |
| | Segmental gross profit | Segmental gross profit | Segmental gross profit | Segmental gross profit |
| | RMB'000 | % | RMB'000 | % |
| | (Unaudited) | | (Unaudited) | |
| Consumer genetic testing services and ancillary services | 56,827 | 94.5% | 67,966 | 97.6% |
| Cancer screening services and ancillary services | 3,313 | 5.5% | 1,652 | 2.4% |
| Total | <u>60,140</u> | <u>100%</u> | <u>69,618</u> | <u>100.0%</u> |

| | For the six months ended | |
|--|--------------------------------------|--------------------------------------|
| | 30 June | |
| | 2025 | 2024 |
| | Segmental gross profit margin | Segmental gross profit margin |
| Consumer genetic testing services and ancillary services | 74.8% | 65.1% |
| Cancer screening services and ancillary services | 62.1% | 57.5% |
| Total | <u>74.0%</u> | <u>64.9%</u> |

- Our gross profit from consumer genetic testing services and ancillary services decreased from RMB68.0 million for the six months ended 30 June 2024 to RMB56.8 million for the same period in 2025. The gross profit margin increased from 65.1% for the six months ended 30 June 2024 to 74.8% for the same period in 2025, which was mainly due to the Company's adjustment of its sales strategy, which led to a short-term decrease in revenue, while also optimizing its product structure, as well as costs such as labor costs, rent and depreciation being relatively fixed.
- Our gross profit from cancer screening services and ancillary services increased from RMB1.6 million for the six months ended 30 June 2024 to RMB3.3 million for the same period in 2025, which was mainly due to our enrichment of product categories for our cancer screening services and ancillary services, while costs such as labor costs and rent being relatively fixed.

Other Income and Gains

Our other income and gains increased by 22.5% from RMB3.4 million for the six months ended 30 June 2024 to RMB4.2 million for the same period in 2025. Such increase was mainly due to the increase in interest income.

Selling and Distribution Expenses

Our selling and distribution expenses decreased by 23.4% from RMB13.6 million for the six months ended 30 June 2024 to RMB10.4 million for the same period in 2025, which was mainly due to the decrease in selling expenses as a result of the decline in revenue.

Administrative Expenses

Our administrative expenses remained stable at RMB17.5 million and RMB18.0 million for the six months ended 30 June 2024 and 2025, respectively.

Impairment (Losses)/Reversal of Impairment on Trade Receivables, Net

We had reversal of impairment on trade receivables, net of RMB2.7 million for the six months ended 30 June 2024, and impairment losses on trade receivables of RMB1.3 million for the six months ended 30 June 2025, which was mainly due to the impact of non-recurring items on the reversal of impairment on trade receivables in 2024, while provision for impairment on trade receivables was made normally in accordance with the relevant provisions of the Accounting Standards for Business Enterprises during the Period.

Other Expenses

For the six months ended 30 June 2024 and 2025, our other expenses were RMB0.6 million and RMB1.0 million, respectively. The increase in other expenses was mainly due to the increase in our external donations during the Reporting Period.

Finance Costs

Our finance costs decreased by 43.6% from RMB0.9 million for the six months ended 30 June 2024 to RMB0.5 million for the same period in 2025. Such decrease was mainly due to the decrease in interest expenses on lease liabilities under the new lease standards.

Income Tax Expenses

Our income tax expenses decreased by 3.2% from RMB6.1 million for the six months ended 30 June 2024 to RMB5.9 million for the same period in 2025. Such decrease was mainly due to the reduction in profit as compared with the same period of 2024.

Profit for the Period

As a result of the above, our profit for the period decreased from RMB37.0 million for the six months ended 30 June 2024 to RMB27.3 million for the same period in 2025.

Cash and Cash Equivalents

For the six months ended 30 June 2025, our net cash used in operating activities was RMB1.3 million, primarily attributable to the slowdown in the collection of trade receivables by the Company during the Reporting Period.

For the six months ended 30 June 2025, our net cash flows generated from investing activities was RMB2.3 million, primarily attributable to the receipt of investment income by the Company.

For the six months ended 30 June 2025, our net cash flows used in financing activities was RMB31.9 million, primarily attributable to the repurchase of shares by the Company.

As a result of the above, our cash and cash equivalents, which were mainly held in RMB and HKD, decreased by 6.3% from RMB490.3 million as of 31 December 2024 to RMB459.5 million as of 30 June 2025.

Indebtedness

Lease Liabilities

As of 31 December 2024 and 30 June 2025, we had outstanding aggregate unpaid contractual lease payments (present value of lease payments for the remainder of relevant lease terms) of RMB13.7 million and RMB20.1 million respectively in relation to the corresponding current and non-current lease liabilities.

As of 30 June 2025, the Company had outstanding bank loans of RMB19.7 million (2024: RMB20.7 million). Among which, RMB2.0 million will mature within one year and RMB17.7 million will mature after one year.

Save as disclosed above, we did not have any outstanding loan, capital issued or agreed to be issued, debt securities, mortgages, charges, debentures, bank overdrafts, loans, unutilized banking facilities or other similar indebtedness, liabilities under acceptances or acceptance credits, hire purchase commitments or other contingent liabilities as of 30 June 2025.

Our Directors have also confirmed that, as of 30 June 2025, there was no material change in the Company's indebtedness since 31 December 2024.

Key Financial Ratios

| | For the six months ended | |
|------------------------------------|--------------------------|-------|
| | 30 June | |
| | 2025 | 2024 |
| Gross profit margin ⁽¹⁾ | 74.0% | 64.9% |
| Net profit margin ⁽²⁾ | 33.5% | 34.5% |
| Current ratio ⁽³⁾ | 15.2 | 5.4 |

Notes:

- (1) Gross profit margin equals gross profit divided by revenue for the period.
- (2) Net profit margin equals net profit divided by revenue for the period.
- (3) Current ratio equals current assets divided by current liabilities as of the end of the period.

Capital Expenditures

Our principal capital expenditures related primarily to the purchase of equipment and the establishment of an automatic laboratory. The table below sets forth our capital expenditures for the periods indicated.

| | For the six months ended | |
|--|--------------------------|-------------|
| | 30 June | |
| | 2025 | 2024 |
| | RMB'000 | RMB'000 |
| | (Unaudited) | (Unaudited) |
| Purchases of property, plant and equipment | 106 | 619 |
| Purchases of other intangible assets | — | 14 |
| Total | <u>106</u> | <u>633</u> |

Contingent Liabilities

As of 30 June 2025, we had no material contingent liabilities.

Significant Investments and Future Plans for Material Investments or Capital Assets

As of 30 June 2025, we did not hold any significant investment.

In addition, save for the expansion plans as disclosed in the two sections headed “Business” and “Future Plans and Use of Proceeds” in the Prospectus, we have no future plans for material investments or capital assets.

Material Acquisitions and Disposals

For the six months ended 30 June 2025, we did not make any material acquisitions or disposals of subsidiaries, associates and joint ventures.

Pledge of Group Assets

As of 30 June 2025, we pledged certain property, plant and equipment in an amount of approximately RMB32.4 million (30 June 2024: RMB34.7 million) to secure bank loans.

Interim Dividend

The Board has resolved not to declare an interim dividend for the six months ended 30 June 2025.

Employees

As of 30 June 2025, we had 203 employees, most of whom were based in Beijing. We conduct new staff training regularly to guide new employees and help them adapt to the new working environment. In addition, we provide online and in-person formal and comprehensive company-level and department-level training to our employees on a quarterly basis in addition to on-the-job training. Employees are also encouraged to attend external seminars and workshops to enrich their technical knowledge and develop competencies and skills. We also provide training and development programs as well as external training courses to our employees from time to time for the sake of enhancing their technical skills and ensuring that they understand and comply with our policies and procedures.

The compensation of our employees is determined with reference to market conditions and the performance, qualifications and experience of individual employees. We offer competitive compensation packages, including salaries, discretionary bonuses and benefit plans, to retain employees based on the performance of us and individual employees.

The Company adopted a restricted share unit scheme (the “**RSU Scheme**”) on 19 November 2021. On 29 December 2022, the Company granted a total of 27,272,000 RSUs to certain eligible participants of the Company under the RSU Scheme, the principal terms and details of which are set out in the section headed “Appendix IV – Statutory and General Information – D. Restricted Share Unit Scheme” of the Prospectus and the announcement of the Company dated 29 December 2022.

Other Material Events

(1) Suspension of trading on the Stock Exchange

Trading in the Shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on 1 April 2025 and will remain suspended until the fulfillment of the resumption guidance as specified by the Stock Exchange.

(2) Resumption guidance

On 23 May 2025, the Company received a letter from the Stock Exchange setting out the guidance for the resumption of trading in the Shares of the Company on the Stock Exchange. The latest resumption guidance (the “**Resumption Guidance**”) as of the date of this announcement is as follows:

- (i) conduct an appropriate independent forensic investigation into the audit issues, assess the impact on the Company’s business operation and financial position, announce the findings and take appropriate remedial actions;
- (ii) demonstrate that there is no reasonable regulatory concern about the integrity, competence and/or character of the Group’s management and/or any persons with substantial influence over the Company’s management and operations, which may pose a risk to investors and damage market confidence;
- (iii) conduct an independent internal control review and demonstrate that the Company has in place adequate internal controls and procedures to meet its obligations under the Listing Rules;
- (iv) publish all outstanding financial results required under the Listing Rules and address any audit modifications;
- (v) demonstrate the Company’s operations complying with Rule 13.24 of the Listing Rules; and
- (vi) inform the market of all material information for the Company’s Shareholders and other investors to appraise its position.

For details regarding the Resumption Guidance, please refer to the announcement of the Company dated 30 May 2025.

(3) Progress of fulfillment of the Resumption Guidance

For quarterly updates on the status of resumption and the Company’s resumption plan in fulfilling the Resumption Guidance, please refer to the announcements of the Company dated 30 June 2025, 30 September 2025 and 31 December 2025.

(4) Appointment of new auditor

The Company has removed Ernst & Young as its auditor and appointed Crowe (HK) CPA Limited as its new auditor with effect from 21 July 2025 until the next annual general meeting of the Company. For details regarding the appointment of new auditor, please refer to the announcements of the Company dated 5 May 2025, 30 June 2025 and 21 July 2025.

(5) Independent forensic investigation

In accordance with the requirements set out in the Resumption Guidance, the Investigation Committee has engaged an independent investigation company to conduct an independent forensic investigation into the audit issues. For the key findings of the investigation report, the opinions of the Investigation Committee and the Board, the recommendations and the status of completion, please refer to the announcement of the Company dated 10 November 2025.

(6) Internal control review

In accordance with the requirements set out in the Resumption Guidance, the Company has engaged an external independent adviser to conduct a review on the Group's internal control systems and procedures and a subsequent review on the remedial measures implemented by the Company. For the key findings of the internal control review, the opinions of the Investigation Committee and the Board, the corrective recommendations and the implementation of remedial actions, please refer to the announcement of the Company dated 12 January 2026.

Material Events After the Reporting Period

Save for the matters disclosed herein, as of the date of this announcement, there were no material events after 30 June 2025 that might have a material impact on our operations and financial results.

**INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND
OTHER COMPREHENSIVE INCOME**

For the six months ended 30 June 2025

| | | 2025 | 2024 |
|---|--------------|-----------------------|-----------------|
| | | (Unaudited) | (Unaudited) |
| | <i>Notes</i> | RMB'000 | RMB'000 |
| REVENUE | 4 | 81,281 | 107,291 |
| Cost of sales | | <u>(21,141)</u> | <u>(37,673)</u> |
| Gross profit | | 60,140 | 69,618 |
| Other income and gains | 4 | 4,210 | 3,438 |
| Selling and distribution expenses | | (10,426) | (13,609) |
| Administrative expenses | | (17,987) | (17,511) |
| Impairment (losses)/reversal of impairment on trade receivables, net | | (1,263) | 2,686 |
| Other expenses | | (1,004) | (643) |
| Finance costs | | <u>(528)</u> | <u>(937)</u> |
| PROFIT BEFORE TAX | 5 | 33,142 | 43,042 |
| Income tax expense | 6 | <u>(5,881)</u> | <u>(6,073)</u> |
| PROFIT AND TOTAL COMPREHENSIVE INCOME FOR THE PERIOD | | <u>27,261</u> | <u>36,969</u> |
| Attributable to: | | | |
| Owners of the parent | | <u>27,261</u> | <u>36,969</u> |
| EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT | 8 | | |
| Basic | | <u>RMB0.13</u> | <u>RMB0.18</u> |
| Diluted | | <u>RMB0.13</u> | <u>RMB0.18</u> |

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2025

| | | 30 June 2025 | 31 December 2024 |
|---|--------------|-------------------------|---------------------|
| | | (Unaudited) | (Audited) |
| | <i>Notes</i> | RMB'000 | RMB'000 |
| NON-CURRENT ASSETS | | | |
| Property, plant and equipment | | 54,544 | 59,038 |
| Right-of-use assets | | 21,131 | 20,222 |
| Intangible assets | | 689 | 770 |
| Financial assets at fair value through profit or loss | | 30,800 | 30,800 |
| Deferred tax assets | | 1,604 | 2,055 |
| | | <hr/> | <hr/> |
| Total non-current assets | | 108,768 | 112,885 |
| | | <hr/> | <hr/> |
| CURRENT ASSETS | | | |
| Inventories | | 5,351 | 4,609 |
| Trade receivables | 9 | 91,940 | 90,056 |
| Prepayments, other receivables and other assets | | 22,510 | 40,667 |
| Cash and cash equivalents | | 459,451 | 490,260 |
| | | <hr/> | <hr/> |
| Total current assets | | 579,252 | 625,592 |
| | | <hr/> | <hr/> |
| CURRENT LIABILITIES | | | |
| Trade payables | 10 | 25,376 | 25,433 |
| Other payables and accruals | | 8,772 | 60,888 |
| Interest-bearing bank and other borrowings | | 2,038 | 1,995 |
| Tax payable | | 1,365 | 1,724 |
| Deferred income | | 600 | 600 |
| | | <hr/> | <hr/> |
| Total current liabilities | | 38,151 | 90,640 |
| | | <hr/> | <hr/> |
| NET CURRENT ASSETS | | 541,101 | 534,952 |
| | | <hr/> | <hr/> |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | 649,869 | 647,837 |
| | | <hr/> | <hr/> |

**INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
(CONTINUED)**

30 June 2025

| | 30 June 2025 (Unaudited) RMB'000 | 31 December 2024 (Audited) RMB'000 |
|--|---|---|
| NON-CURRENT LIABILITIES | | |
| Interest-bearing bank and other borrowings | 17,698 | 18,728 |
| Lease liabilities | 20,121 | 13,679 |
| Deferred income | 450 | 750 |
| | <hr/> | <hr/> |
| Total non-current liabilities | 38,269 | 33,157 |
| | <hr/> | <hr/> |
| Net assets | 611,600 | 614,680 |
| | <hr/> <hr/> | <hr/> <hr/> |
| EQUITY | | |
| Share capital | 145 | 150 |
| Treasury shares | – | (27,979) |
| Reserves | 611,455 | 642,509 |
| | <hr/> | <hr/> |
| Total equity | 611,600 | 614,680 |
| | <hr/> <hr/> | <hr/> <hr/> |

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2025

1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2025 has been prepared in accordance with HKAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.

2. ACCOUNTING POLICIES

2.1 Changes in Accounting Policies and Disclosures

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of the following revised Hong Kong Financial Reporting Standards (“HKFRSs”) for the first time for the current period's financial information.

| | |
|----------------------------------|---|
| Amendments to HKFRS 16 | <i>Lease Liability in a Sale and Leaseback</i> |
| Amendments to HKAS 1 | <i>Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (the “2020 Amendments”)</i> |
| Amendments to HKAS 1 | <i>Non-current Liabilities with Covenants (the “2022 Amendments”)</i> |
| Amendments to HKAS 7 and HKFRS 7 | <i>Supplier Finance Arrangements</i> |

The nature and impact of the revised HKFRSs are described below:

- (a) Amendments to HKFRS 16 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains. Since the Group has no sale and leaseback transactions with variable lease payments that do not depend on an index or a rate occurring from the date of initial application of HKFRS 16, the amendments did not have any impact on the financial position or performance of the Group.

- (b) The 2020 Amendments clarify the requirements for classifying liabilities as current or non-current, including what is meant by a right to defer settlement and that a right to defer must exist at the end of the reporting period. Classification of a liability is unaffected by the likelihood that the entity will exercise its right to defer settlement. The amendments also clarify that a liability can be settled in its own equity instruments, and that only if a conversion option in a convertible liability is itself accounted for as an equity instrument would the terms of a liability not impact its classification. The 2022 Amendments further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. Additional disclosures are required for non-current liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period.

The Group has reassessed the terms and conditions of its liabilities as at 1 January 2024 and 2025 and concluded that the classification of its liabilities as current or non-current remained unchanged upon initial application of the amendments. Accordingly, the amendments did not have any impact on the financial position or performance of the Group.

- (c) Amendments to HKAS 7 and HKFRS 7 clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk. The disclosure of relevant information for supplier finance arrangements is not required for any interim reporting period during the first annual reporting period in which an entity applies the amendments. As the Group does not have supplier finance arrangements, the amendments did not have any impact on the interim condensed consolidated financial information.

2.2 Issued But Not Yet Effective HKFRS Accounting Standards

The Group has not applied the following new and revised HKFRSs, that have been issued but are not yet effective, in the financial statements. The Group intends to apply these new and revised HKFRSs, if applicable, when they become effective.

| | |
|--|---|
| HKFRS 18 and consequential amendments to other HKFRSs | <i>Presentation and Disclosure in Financial Statements</i> ³ |
| HKFRS 19 | <i>Subsidiaries without Public Accountability: Disclosures</i> ³ |
| Amendments to HKFRS 9 and HKFRS 7 | <i>Amendments to the Classification and Measurement of Financial Instruments</i> ² |
| Amendments to HKFRS 9 and HKFRS 7 | <i>Contracts Referencing Nature-dependent Electricity</i> ² |
| Amendments to HKFRS 10 and HKAS 28 | <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i> ⁴ |
| Amendments to HKAS 21 | <i>Lack of Exchangeability</i> ¹ |
| <i>Annual Improvements to HKFRS Accounting Standards – Volume 11</i> | Amendments to HKFRS 1, HKFRS 7, HKFRS 9, HKFRS 10 and HKAS 7 ² |

¹ Effective for annual periods beginning on or after 1 January 2025

² Effective for annual periods beginning on or after 1 January 2026

³ Effective for annual periods beginning on or after 1 January 2027

⁴ No mandatory effective date yet determined but available for adoption

Further information about those HKFRSs that are expected to be applicable to the Group is described below.

HKFRS 18 replaces HKAS 1 *Presentation of Financial Statements*. While a number of sections have been brought forward from HKAS 1 with limited changes, HKFRS 18 introduces new requirements for presentation within the statement of profit or loss, including specified totals and subtotals. Entities are required to classify all income and expenses within the statement of profit or loss into one of the five categories: operating, investing, financing, income taxes and discontinued operations and to present two new defined subtotals. It also requires disclosures about management-defined performance measures in a single note and introduces enhanced requirements on the grouping (aggregation and disaggregation) and the location of information in both the primary financial statements and the notes. Some requirements previously included in HKAS 1 are moved to HKAS 8 *Accounting Policies, Changes in Accounting Estimates and Errors*, which is renamed as HKAS 8 *Basis of Preparation of Financial Statements*. As a consequence of the issuance of HKFRS 18, limited, but widely applicable, amendments are made to HKAS 7 *Statement of Cash Flows*, HKAS 33 *Earnings per Share* and HKAS 34 *Interim Financial Reporting*. In addition, there are minor consequential amendments to other HKFRSs. HKFRS 18 and the consequential amendments to other HKFRSs are effective for annual periods beginning on or after 1 January 2027 with earlier application permitted. Retrospective application is required. The Group is currently analysing the new requirements and assessing the impact of HKFRS 18 on the presentation and disclosure of the Group's financial statements.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is not organised into business units based on their services and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

| | For the six months ended | |
|---------------------------------------|---------------------------------|-------------|
| | 30 June | |
| | 2025 | 2024 |
| | (Unaudited) | (Unaudited) |
| | RMB'000 | RMB'000 |
| Revenue from contracts with customers | 81,281 | 107,291 |

Revenue from contracts with customers

(a) Disaggregated revenue information

| | For the six months ended | |
|--|--------------------------|----------------|
| | 30 June | |
| | 2025 | 2024 |
| | (Unaudited) | (Unaudited) |
| | RMB'000 | RMB'000 |
| Types of goods or services | | |
| Consumer genetic testing services and ancillary services | 75,947 | 104,419 |
| Cancer screening services and ancillary services | 5,334 | 2,872 |
| | <u>81,281</u> | <u>107,291</u> |
| Total | <u>81,281</u> | <u>107,291</u> |
| Timing of revenue recognition | | |
| Goods or services transferred at a point in time | <u>81,281</u> | <u>107,291</u> |

Geographical markets

All of the Group's revenues were generated from customers located in Mainland China during the reporting periods.

(b) Performance obligation

Information about the Group's performance obligation is summarised below:

Genetic testing services

The performance obligation of genetic testing services is satisfied upon delivery of testing reports and payment is generally due within three to six months from the date of billing, except for certain customers, where payment in advance is required. The performance obligation of sale of relevant medical materials is satisfied upon receipt of materials by customers and payment is generally due within three to six months from the date of billing, except for certain customers, where payment in advance is required.

An analysis of other income and gains is as follows:

| | For the six months ended 30 June | |
|---|---|-----------------------|
| | 2025 | 2024 |
| | (Unaudited) | (Unaudited) |
| | <i>RMB'000</i> | <i>RMB'000</i> |
| Other income and gains | | |
| Rental income | – | 503 |
| Bank interest income | 1,346 | 653 |
| Government grants | 406 | 349 |
| Investment income from financial assets at fair value through profit or loss | 2,436 | 1,869 |
| Foreign exchange differences, net | 10 | – |
| Others | 12 | 64 |
| | <u>4,210</u> | <u>3,438</u> |
| Total | <u>4,210</u> | <u>3,438</u> |

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging:

| | For the six months ended 30 June | |
|---|---|-----------------------|
| | 2025 | 2024 |
| | (Unaudited) | (Unaudited) |
| | <i>RMB'000</i> | <i>RMB'000</i> |
| Cost of services provided | 21,141 | 37,673 |
| Depreciation of property, plant and equipment | 4,600 | 3,808 |
| Depreciation of right-of-use assets | 2,800 | 3,307 |
| Amortisation of intangible assets | 81 | 81 |
| Research and development costs | 8,151 | 9,934 |
| Foreign exchange loss/(gain), net | (10) | 122 |
| Impairment losses on trade receivable, net | 1,263 | (2,686) |
| | <u>1,263</u> | <u>(2,686)</u> |

6. INCOME TAX EXPENSE

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the rules and regulations of the Cayman Islands, the Company is not subject to any income tax in this jurisdiction.

The statutory tax rate for the subsidiary in Hong Kong is 16.5%. No Hong Kong profits tax on the subsidiary has been provided as there was no assessable profit arising in Hong Kong during the reporting periods.

The provision for current income tax in Mainland China is based on a statutory tax rate of 25% of the assessable profits of the PRC subsidiaries of the Group as determined in accordance with the PRC Corporate Income Tax Law, except for Mega Genomics Beijing, a subsidiary of the Group. Mega Genomics Beijing is qualified as a High and New Technology Enterprise and was subject to tax at a preferential income tax rate of 15% during the reporting periods.

The income tax expense of the Group is analysed as follows:

| | For the six months ended 30 June | |
|---------------------------------|---|---------------------|
| | 2025 | 2024 |
| | (Unaudited) | (Unaudited) |
| | RMB'000 | RMB'000 |
| Current tax | 5,430 | 5,004 |
| Deferred tax | 451 | 1,069 |
| | <hr/> | <hr/> |
| Total tax charge for the period | <u>5,881</u> | <u>6,073</u> |

7. DIVIDENDS

No dividend has been declared and paid by the Company in respect of the reporting period (six months ended 30 June 2024: Nil).

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amount is based on the profit for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 204,428,047 (2024: 209,637,209) in issue during the period. The number of shares for the current period has been arrived at after eliminating the shares held under the restricted share unit scheme.

The calculation of the diluted earnings per share amount presented for the period ended 30 June 2025 is based on the profit for the period attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed conversion of all dilutive potential ordinary shares into ordinary shares.

No adjustment has been made to the basic earnings per share amount presented for the six months period ended 30 June 2025 in respect of a dilution as the impact of the restricted share unit scheme had an anti-dilutive effect on the basic earnings per share amount presented.

The calculations of basic and diluted earnings per share are based on:

| | For the six months ended 30 June | |
|---|---|--------------------|
| | 2025 | 2024 |
| | (Unaudited) | (Unaudited) |
| | RMB'000 | RMB'000 |
| Earnings | | |
| Profit attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation | <u>27,261</u> | <u>36,969</u> |
| | | |
| | Number of shares | |
| | For the six months ended 30 June | |
| | 2025 | 2024 |
| | (Unaudited) | (Unaudited) |
| Shares | | |
| Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation | 204,428,047 | 209,637,209 |
| Effect of dilution – weighted average number of ordinary shares: Restricted share unit scheme | <u>–</u> | <u>–</u> |
| Total | <u>204,428,047</u> | <u>209,637,209</u> |

9. TRADE AND NOTES RECEIVABLES

| | 30 June 2025 (Unaudited) RMB'000 | 31 December 2024 (Audited) RMB'000 |
|---------------------|---|---|
| Trade receivables | 109,750 | 105,371 |
| Impairment | (17,826) | (16,564) |
| | <u> </u> | <u> </u> |
| Net carrying amount | 91,924 | 88,807 |
| | <u> </u> | <u> </u> |
| Notes receivables | 16 | 1,249 |
| | <u> </u> | <u> </u> |

The Group's trading terms with its customers are mainly on credit. The credit terms granted generally ranged from three to six months, depending on the specific payment terms in each contract. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

Included in the Group's trade receivables were amounts due from related parties of RMB50,130,000 as at 30 June 2025 (2024: RMB81,011,000), which are repayable on credit terms similar to those offered to the customers of the Group.

An ageing analysis of the trade receivables as at the end of the reporting periods, based on the invoice date and net of loss allowance, is as follows:

| | 30 June 2025 (Unaudited) RMB'000 | 31 December 2024 (Audited) RMB'000 |
|-------------------|---|---|
| Within 3 months | 10,578 | 30,226 |
| 3 to 6 months | 7,689 | 10,431 |
| 6 to 12 months | 29,043 | 9,902 |
| 1 to 2 years | 39,802 | 36,906 |
| Over 2 years | 4,812 | 1,342 |
| | <u> </u> | <u> </u> |
| Total | 91,924 | 88,807 |
| | <u> </u> | <u> </u> |
| Notes receivables | | |
| Within 3 months | 16 | 1,249 |
| | <u> </u> | <u> </u> |

10. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting periods, based on the invoice date, is as follows:

| | 30 June 2025 (Unaudited) RMB'000 | 31 December 2024 (Audited) RMB'000 |
|-----------------|---|---|
| Within 3 months | 7,342 | 6,407 |
| 3 to 6 months | 3,724 | 3,217 |
| 6 to 12 months | 6,370 | 11,037 |
| Over 12 months | 7,940 | 4,772 |
| | <hr/> | <hr/> |
| Total | 25,376 | 25,433 |

The trade payables are non-interest-bearing and are normally settled within six months.

Included in the Group's trade payables were amounts due to related parties of RMB124,000 as at 30 June 2025 (2024: RMB174,000) with credit terms similar to those offered by the related parties to their customers.

11. RELATED PARTY TRANSACTIONS

Details of the Group's related parties are as follows:

| Company | Relationship with the Company |
|--|--------------------------------------|
| Dr. Yu Rong | Shareholder and director |
| Meinian Onehealth Healthcare Holdings Co., Ltd. and its subsidiaries ("Meinian Onehealth") | Shareholder |

- (a) The Group had the following transactions with related parties during the periods:

| | For the six months ended | |
|---|---------------------------------|----------------------|
| | 30 June | |
| | 2025 | 2024 |
| | (Unaudited) | (Unaudited) |
| | RMB'000 | RMB'000 |
| Services provided to: | | |
| Meinian Onehealth | 64,439 | 41,542 |
| Companies controlled by Dr. Yu Rong | – | 3,834 |
| | <u> </u> | <u> </u> |
| Total | <u>64,439</u> | <u>45,376</u> |
| Services provided by: | | |
| Meinian Onehealth and its subsidiaries | – | 25 |
| | <u> </u> | <u> </u> |
| Property management services provided by: | | |
| A company controlled by Dr. Yu Rong | 645 | 668 |
| | <u> </u> | <u> </u> |

- (b) Outstanding balances with related parties:

| | 30 June | 31 December |
|--|----------------------|----------------------|
| | 2025 | 2024 |
| | (Unaudited) | (Audited) |
| | RMB'000 | RMB'000 |
| Trade receivables | | |
| Meinian Onehealth and its subsidiaries | 40,583 | 44,182 |
| Companies controlled by Dr. Yu Rong | 3,713 | 36,829 |
| | <u> </u> | <u> </u> |
| Total | <u>44,296</u> | <u>81,011</u> |
| Other receivables | | |
| Companies controlled by Dr. Yu Rong | 4,390 | 4,390 |
| | <u> </u> | <u> </u> |
| Prepayments | | |
| Meinian Onehealth and its subsidiaries | 820 | 820 |
| | <u> </u> | <u> </u> |

| | 30 June 2025 (Unaudited) RMB'000 | 31 December 2024 (Audited) RMB'000 |
|--|---|---|
| Trade payables | | |
| Meinian Onehealth and its subsidiaries | <u>124</u> | <u>174</u> |
| Contract liabilities | | |
| Meinian Onehealth and its subsidiaries | 15,448 | 43,361 |
| Companies controlled by Dr. Yu Rong | <u>–</u> | <u>125</u> |
| Total | <u>15,448</u> | <u>43,486</u> |
| Lease liabilities | | |
| Companies controlled by Dr. Yu Rong | <u>20,121</u> | <u>13,679</u> |

(c) Compensation of key management personnel of the Group:

| | For the six months ended 30 June | |
|---|---|--------------------------------|
| | 2025 (Unaudited) RMB'000 | 2024 (Unaudited) RMB'000 |
| Salaries, allowances and benefits in kind | 971 | 1,137 |
| Pension scheme contributions | 159 | 52 |
| Share-based payment expense | <u>–</u> | <u>357</u> |
| Total compensation paid to key management personnel | <u>1,129</u> | <u>1,546</u> |

ADDITIONAL INFORMATION

Purchase, Sale or Redemption of the Company's Listed Securities

During the Reporting Period, the Company has repurchased a total of 3,834,000 shares of the Company on the Stock Exchange for a total consideration of HK\$32,897,016.

Details of the repurchase are set out as follows:

| Month | Total number of shares repurchased | Price per share | | Total consideration <i>HK\$</i> |
|---------------|--|-----------------|-------------|---------------------------------------|
| | | Highest | Lowest | |
| | | <i>HK\$</i> | <i>HK\$</i> | |
| January 2025 | 1,098,000 | 10.30 | 8.60 | 10,382,260 |
| February 2025 | 2,736,000 | 9.46 | 7.27 | 22,514,756 |
| Total | <u>3,834,000</u> | | | <u>32,897,016</u> |

As of 30 June 2025, the Company has cancelled all of shares repurchased above.

The repurchase was effected for enhancing the net assets per share and earnings per share and in accordance with the repurchase mandate granted to the Board in the 2024 annual general meeting of the Company.

Save as disclosed above, neither the Company nor its subsidiaries have purchased, sold or redeemed any of the Company's listed securities as of 30 June 2025.

Compliance with the Corporate Governance Code

The Company is committed to maintaining and promoting stringent corporate governance. The principle of the Company's corporate governance is to promote effective internal control measures, uphold a high standard of ethics, transparency, responsibility and integrity in all aspects of business, to ensure that its affairs are conducted in accordance with applicable laws and regulations and to enhance the transparency and accountability system of the Board to all shareholders.

The Company has adopted the Corporate Governance Code (the "CG Code") contained in Appendix C1 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules") as its own code of corporate governance. The Board is of the view that, during the Reporting Period, the Company has complied with the code provisions as set out in the CG Code.

Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as set out in Appendix C3 to the Listing Rules as the Group’s code of conduct regarding the Directors’ securities transactions. Having made specific enquiry of all the Directors, all the Directors confirmed that they have strictly complied with the Model Code during the Reporting Period.

Save as disclosed in this announcement, from 1 January 2025 to 30 June 2025, there were no other material changes in respect of the Company that needed to be disclosed under paragraph 46 of Appendix D2 to the Listing Rules.

Audit Committee and Review of Financial Information

The Board has established an audit committee (the “**Audit Committee**”) with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code. As of the date of this announcement, the Audit Committee consists of three members, namely Mr. Jia Qingfeng, Ms. Guo Meiling and Dr. Zhang Ying. Mr. Jia Qingfeng, being the chairman of the Audit Committee, holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit Committee include, without limitation, assisting the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Group and overseeing the audit process.

The Audit Committee has reviewed the Group’s unaudited interim financial information for the six months ended 30 June 2025. The Audit Committee has also reviewed the accounting principles adopted by the Group and discussed auditing, internal control, risk management and financial reporting matters.

Publication of Interim Results Announcement and Interim Report

This interim results announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.megagenomics.cn). The interim report of the Company for the six months ended 30 June 2025 containing all the information required by the Listing Rules will be made available on the same websites and/or despatched to the shareholders of the Company in due course.

By order of the Board
Mega Genomics Limited
Lin Lin
Executive Director and Chairperson

Hong Kong, 4 February 2026

As of the date of this announcement, the executive Directors of the Company are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director of the Company is Ms. Guo Meiling; and the independent non-executive Directors of the Company are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.